Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 3—March 2011
Research

Monitoring and Characterization of Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, Japan, 2009–2010

Makoto Ujike, Miho Ejima, Akane Anraku, Kozue Shimabukuro, Masatsugu Obuchi, Noriko Kishida, Xu Hong, Emi Takashita, Seiichiro Fujisaki, Kazuyo Yamashita, Hiroshi Horikawa, Yumiko Kato, Akio Oguchi, Nobuyuki Fujita, Masato Tashiro, Takato OdagiriComments to Author , and the Influenza Virus Surveillance Group of Japan
Author affiliations: Author affiliations: National Institute of Infectious Diseases, Tokyo, Japan (M. Ujike, M. Ejima, A. Anraku, K. Shimabukuro, M. Obuchi, N. Kishida, X. Hong, E. Takashita, S. Fujisaki, K. Yamashita, M. Tashiro, T. Odagiri); National Institute of Technology and Evaluation, Tokyo (H. Horikawa, Y. Kato, A. Oguchi, N. Fujita)

Main Article

Table1

Relationship between detection of oseltamivir-resistant pandemic (H1N1) 2009 and interval from oseltamivir treatment to sample collection, Japan, 2009–2010*

No. samples
 Days after oseltamivir treatment, N = 516†
Unknown
 0‡
 1
 2
 3
 4
 5
 6
 7
 8
 9
 >10
Total no. 169 54 116 54 37 31 36 7 6 1 3 2
No. oseltamivir-resistant pandemic (H1N1) 2009 3 0 4 2 4 (1) 13 (1) 19 (1) 3 (2) 2 1 (1) 2 (2) 2 (2)

*Of total 4,307 specimens tested, neuraminidase inhibitor treatment history was available for 1,707; of these specimens, 516 were from patients who had received oseltamivir treatment.
†Parentheses indicate prophylactic use, e.g., 4 (1) = 1 of 4 total uses was for prophylaxis.
‡Day 0 represents the samples collected within 24 h after oseltamivir use.

Main Article

1Members of the Influenza Virus Surveillance Group of Japan are listed at the end of this article.

Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external